ClinicalTrials.gg
CompletedNCT00674323PCVUpdated Apr 19, 2011Results posted

Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy

A Phase 4 interventional study of Verteporfin Photodynamic Therapy and Ranibizumab in Polypoidal Choroidal Vasculopathy, sponsored by Novartis. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.

Sponsored by Novartis · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with symptomatic macular polypoidal choroidal vasculopathy.

02

Conditions studied

  • Polypoidal Choroidal Vasculopathy

Keywords

  • Polypoidal choroidal vasculopathy
  • PCV
  • Age-related macular degeneration (AMD) variant
  • vision
  • polyps
  • indocyanine green angiography
  • verteporfin
  • ranibizumab
  • photodynamic therapy
03

In context

Polypoidal Choroidal Vasculopathy

54 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 6 are open to participants now.

This study's enrollment of 61 is above the median of 50 across 39 interventional studies indexed under Polypoidal Choroidal Vasculopathy.

Browse Polypoidal Choroidal Vasculopathy studies →

Lead sponsor

Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must give written before any assessment is performed.
  • Male or Female patients ≥18 yrs of age
  • Patients willing and able to comply with all study procedures

Inclusion criteria for study eye:

  • BCVA letter score between 73-24 (approximately 20/40 to 20/320 Snellen equivalent) using ETDRS visual acuity chart measured at 4 meters
  • PCV diagnosis confirmed by Central Reading Center
  • Greatest Linear Dimension (GLD) of the total lesion area \< 5400 µm (\~9 Macular Photocoagulation Study Disc Areas)

Exclusion Criteria:

  • Women of who are not using one or more reliable methods
  • Pregnant or nursing (lactating) women
  • History of or allergy to fluorescein or indocyanine green (ICG), drug allergy or known hypersensitivity to therapeutic or diagnostic protein products, or to any of the study drugs or their components
  • Patient with history of porphyria
  • Systemic medications known to be toxic to the lens, retina, or optic nerve
  • History of which might affect the interpretation of the results of the study, or renders the patient at high risk from treatment complications
  • Use of other drugs within 30 days of randomization

Exclusion criteria for study eye:

  • Concomitant conditions/diseases:
  • Presence of angioid streaks, macular fibrosis, presumed ocular histoplasmosis syndrome, pathologic myopia (-8 Diopters or more)
  • Active ocular inflammation or infection
  • Uncontrolled glaucoma
  • Ocular disorders that may confound interpretation of study results

Prior Ocular treatment:

  • Prior Verteporfin PDT, external-beam radiation, laser photocoagulation, macular surgery, or transpupillary thermotherapy
  • Prior local treatment with Pegaptanib, Ranibizumab, Bevacizumab or other anti-angiogenic compound or any investigational treatment in both eyes or systemic use of bevacizumab within 90 days prior to randomization
  • History of intraocular surgery including pars plana vitrectomy and intraocular hemorrhage displacement is not allowed with the exception of uncomplicated cataract surgery that is allowed within 60 days prior to screening
  • Ocular conditions that required chronic concomitant therapy within 90 days prior to randomization with topical, ocular, or systemically administered or any herbal medication known to contain steroid-like components

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Verteporfin and Ranibizumab

    Photodynamic therapy with verteporfin in combination with ranibizumab injection. Patients received one treatment at baseline with verteporfin photodynamic therapy (PDT) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.

    Drug: Verteporfin Photodynamic Therapy · Drug: Ranibizumab

  • Active comparator
    Verteporfin monotherapy

    Patients received one treatment at baseline with verteporfin photodynamic therapy in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab placebo (sham intravitreal injection) on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.

    Drug: Verteporfin Photodynamic Therapy

  • Active comparator
    Ranibizumab monotherapy

    Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.

    Drug: Ranibizumab

Interventions

  • After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.

    Also known as: Visudyne

  • Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA)

    Indocyanine green angiography (ICGA) assessments were performed using the Heidelberg Retinal Angiography 2 (HRA2) machine to measure the Total Lesion Area and the degree of polyp regression. Complete regression was defined as no polyps seen on the imaging.

    Time frame: Month 6

Secondary outcomes

  1. Number of Participants With at Least One Complete Polyp Regression During 6 Months Assessed by ICGA

    Indocyanine green angiography (ICGA) assessments were performed using the Heidelberg Retinal Angiography 2 (HRA2) machine to measure the Total Lesion Area and the degree of polyp regression. Complete regression was defined as no polyps seen on the imaging.

    Time frame: Baseline through end of study (6 months)

  2. Mean Change From Baseline in Central Retinal Thickness Measured by Optic Coherence Tomography (OCT)

    High resolution 6 meridian scans were performed to measure central retinal thickness.

    Time frame: Baseline and Month 6

  3. Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 6

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.

    Time frame: Baseline and Month 6

07

Results

Posted Jan 25, 2011

Participant flow

Participant flow — Overall Study
MilestoneVerteporfin and RanibizumabVerteporfin MonotherapyRanibizumab Monotherapy
Started192121
Completed182021
Not completed110
Withdrew: Adverse event010
Withdrew: Protocol violation100

Outcome measures

PrimaryNumber of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA)

Indocyanine green angiography (ICGA) assessments were performed using the Heidelberg Retinal Angiography 2 (HRA2) machine to measure the Total Lesion Area and the degree of polyp regression. Complete regression was defined as no polyps seen on the imaging.

Time frame:
Month 6
Reported as:
Number · Participants
Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA)
ParticipantsVerteporfin and RanibizumabVerteporfin MonotherapyRanibizumab Monotherapy
Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA)14156
SecondaryNumber of Participants With at Least One Complete Polyp Regression During 6 Months Assessed by ICGA

Indocyanine green angiography (ICGA) assessments were performed using the Heidelberg Retinal Angiography 2 (HRA2) machine to measure the Total Lesion Area and the degree of polyp regression. Complete regression was defined as no polyps seen on the imaging.

Time frame:
Baseline through end of study (6 months)
Reported as:
Number · Participants
Number of Participants With at Least One Complete Polyp Regression During 6 Months Assessed by ICGA
ParticipantsVerteporfin and RanibizumabVerteporfin MonotherapyRanibizumab Monotherapy
Number of Participants With at Least One Complete Polyp Regression During 6 Months Assessed by ICGA15189
SecondaryMean Change From Baseline in Central Retinal Thickness Measured by Optic Coherence Tomography (OCT)

High resolution 6 meridian scans were performed to measure central retinal thickness.

Time frame:
Baseline and Month 6
Reported as:
Mean · micrometers
Mean Change From Baseline in Central Retinal Thickness Measured by Optic Coherence Tomography (OCT)
micrometersVerteporfin and RanibizumabVerteporfin MonotherapyRanibizumab Monotherapy
Baseline324.1 ± 112.72285.3 ± 105.64268.5 ± 97.84
Change from Baseline at month 6-145.6 ± 118.97-98.1 ± 104.33-65.7 ± 114.32
SecondaryMean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 6

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.

Time frame:
Baseline and Month 6
Reported as:
Mean · Letters
Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 6
LettersVerteporfin and RanibizumabVerteporfin MonotherapyRanibizumab Monotherapy
Baseline59.8 ± 16.2157.2 ± 12.7649.0 ± 18.05
Change from Baseline at Month 610.9 ± 10.927.5 ± 10.659.2 ± 12.39

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Verteporfin and Ranibizumab—1/19 (5.3%)8/19 (42.1%)
Verteporfin Monotherapy—1/21 (4.8%)9/21 (42.9%)
Ranibizumab Monotherapy—2/21 (9.5%)4/21 (19%)
Most frequent serious events
Most frequent serious events
EventVerteporfin and RanibizumabVerteporfin MonotherapyRanibizumab Monotherapy
Upper respiratory tract infectionInfections and infestations1/190/210/21
Angina pectorisCardiac disorders0/190/211/21
Biliary tract infectionInfections and infestations0/191/210/21
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/191/210/21
DizzinessNervous system disorders0/190/211/21
Most frequent other events
Showing 10 of 17
Most frequent other events
EventVerteporfin and RanibizumabVerteporfin MonotherapyRanibizumab Monotherapy
NasopharyngitisInfections and infestations1/194/210/21
Retinal haemorrhage (Study eye)Eye disorders2/193/210/21
ToothacheGastrointestinal disorders2/190/210/21
DyspnoeaRespiratory, thoracic and mediastinal disorders2/190/210/21
Conjunctival hyperaemia (Study eye)Eye disorders1/190/210/21
Dry eye (Study eye)Eye disorders1/191/210/21
Macular oedema (Study eye)Eye disorders1/190/210/21
Polypoidal choroidal vasculopathy (Fellow eye)Eye disorders1/190/210/21
Visual impairment (Study eye)Eye disorders1/190/210/21
Dental cariesGastrointestinal disorders1/190/210/21

Baseline characteristics

Age Continuous
Age Continuous(years)Verteporfin and RanibizumabVerteporfin MonotherapyRanibizumab MonotherapyTotal
Mean63.8 ± 8.3062.2 ± 9.7769.3 ± 8.2765.1 ± 9.21
Sex: Female, Male
Sex: Female, Male(Participants)Verteporfin and RanibizumabVerteporfin MonotherapyRanibizumab MonotherapyTotal
Female86620
Male11151541
08

Study locations

5 sites
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Seoul, Korea, Republic of
  • Novartis Investigative Site
    Singapore, Singapore
  • Novartis Investigative Site
    Taipei, Taiwan
  • Novartis Investigative Site
    Bangkok, Thailand
09

References and documents

Publications

  • Tan CS, Ngo WK, Chen JP, Tan NW, Lim TH; EVEREST Study Group. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015 May;99(5):624-8. doi: 10.1136/bjophthalmol-2014-305674. Epub 2015 Mar 10. PubMed 25758601 ↗
  • Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012 Sep;32(8):1453-64. doi: 10.1097/IAE.0b013e31824f91e8. PubMed 22426346 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008 and a primary completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2008
First posted
May 7, 2008
Start
Apr 2008
Primary completionActual
May 2009
Results first posted
Jan 25, 2011
Last update
Apr 19, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00674323
Lead sponsor
Novartis
First posted
May 7, 2008
Start date
Apr 2008
Primary completion
May 2009
Results posted
Jan 25, 2011
Last update
Apr 19, 2011

Study contacts

Novartis Pharmaceuticals
study chair · Novartis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Verteporfin · Ranibizumab

Start the discussion